Loading...
Pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts): Impact of blood-based biomarkers on survival outcomes
Ortega-Franco, Ana Tay, R. Raja, H. Ackermann, C. J. Carter, Mathew Lindsay, Colin R Hughes, Sarah Cove-Smith, Laura Taylor, P. Summers, Yvonne J
Ortega-Franco, Ana
Tay, R.
Raja, H.
Ackermann, C. J.
Carter, Mathew
Lindsay, Colin R
Hughes, Sarah
Cove-Smith, Laura
Taylor, P.
Summers, Yvonne J
Citations
Altmetric:
Abstract
Background: The Lung Immune Prognostic Index (LIPI) utilises derived neutrophillymphocyte
ratio (dNLR) and LDH to define prognostic subgroups associated with
overall survival (OS) and overall response rate (ORR) to immune-checkpoint inhibitors
(Mezquita L et al, JAMA Oncol 2018).
Methods: Pre-treated advanced NSCLC pts who received Pembrolizumab (P) at The
Christie (Jan ’17-July ’19) were identified. Baseline demographics, PD-L1 tumour
proportion score (TPS), and LIPI score were collected. We assessed progression free
survival (PFS) and OS using Kaplan-Meier method and performed a comparative
analysis of LIPI score and PD-L1 TPS on survival.
Results: 111 consecutive pts were analysed (Table shows baseline demographics).
After a median follow up of 11.2 months, 77.5% of pts progressed. ORR was 26.1%.
Median PFS and OS were 4 (1.6-6.4) and 13 (10.2-15.8) months (mos), respectively.
OS was 10 vs 19 mos (HR 0.50, 95%CI 0.3-0.8; p¼0.006) for TPS 1-49% and 50%,
respectively. OS for good vs intermediate vs poor LIPI score was 14, 11 and 3 mos
(HR 1.5, 95% CI 1.1-2.3; p¼0.018), respectively. 36.9% of pts experienced immune
related adverse events (irAEs), 10.8% being grade 3-5. Toxicity-related discontinuation
rate was 14.4%. LIPI score and high TPS remained prognostic factors in a
multivariate model including ECOG, smoking status and irAEs. 40% of pts received
4 cycles, mostly due to early disease progression (EDP). Pts with EDP had shorter OS
(4 vs 19 mos, P<0.005). Next generation sequencing analysis for this subgroup is ongoing
Description
Date
2020
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 77.26 KB
Keywords
Type
Meetings and Proceedings
Citation
Ortega Franco A, Tay R, Raja H, Ackermann CJ, Carter M, Lindsay C, et al. 108P Pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts): Impact of blood-based biomarkers on survival outcomes. Annals of Oncology. 2020;31:S284-S.